Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells.

Emi Sano, Sayaka Deguchi, Ayaka Sakamoto, Natsumi Mimura, Ai Hirabayashi, Yukiko Muramoto, Takeshi Noda, Takuya Yamamoto, Kazuo Takayama
Author Information
  1. Emi Sano: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.
  2. Sayaka Deguchi: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.
  3. Ayaka Sakamoto: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.
  4. Natsumi Mimura: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.
  5. Ai Hirabayashi: Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
  6. Yukiko Muramoto: Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
  7. Takeshi Noda: Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
  8. Takuya Yamamoto: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.
  9. Kazuo Takayama: Center for iPS Cell Research and Application (CiRA), Kyoto University, Shogoin Kawaharacho 53, Sakyo-ku, Kyoto 606-8507, Japan.

Abstract

Genetic differences are a primary reason for differences in the susceptibility and severity of COVID-19. As induced pluripotent stem (iPS) cells maintain the genetic information of the donor, they can be used to model individual differences in SARS-CoV-2 infection . We found that human iPS cells expressing the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) (ACE2-iPS cells) can be infected w SARS-CoV-2. In infected ACE2-iPS cells, the expression of SARS-CoV-2 nucleocapsid protein, budding of viral particles, and production of progeny virus, double membrane spherules, and double-membrane vesicles were confirmed. We performed SARS-CoV-2 infection experiments on ACE2-iPS/ embryonic stem (ES) cells from eight individuals. Male iPS/ES cells were more capable of producing the virus compared with female iPS/ES cells. These findings suggest that ACE2-iPS cells can not only reproduce individual differences in SARS-CoV-2 infection but also are a useful resource to clarify the causes of individual differences in COVID-19 due to genetic differences.

Keywords

References

  1. N Engl J Med. 2020 Oct 15;383(16):1522-1534 [PMID: 32558485]
  2. mBio. 2020 Sep 18;11(5): [PMID: 32948688]
  3. Nat Commun. 2020 Nov 18;11(1):5885 [PMID: 33208793]
  4. Lancet. 2020 Mar 28;395(10229):1014-1015 [PMID: 32197108]
  5. Hum Genomics. 2020 Oct 22;14(1):40 [PMID: 33092637]
  6. Signal Transduct Target Ther. 2020 Dec 4;5(1):283 [PMID: 33277466]
  7. Nature. 2021 Jan;589(7841):270-275 [PMID: 33116299]
  8. Cell. 2008 Sep 5;134(5):877-86 [PMID: 18691744]
  9. Cell. 2020 Apr 16;181(2):271-280.e8 [PMID: 32142651]
  10. Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):23274-23283 [PMID: 31591190]
  11. mBio. 2013 Oct 22;4(5):e00801-13 [PMID: 24149513]
  12. Drug Dev Res. 2020 Nov;81(7):771-776 [PMID: 32412125]
  13. Cell. 2020 May 28;181(5):1016-1035.e19 [PMID: 32413319]
  14. Nature. 2020 Nov;587(7835):610-612 [PMID: 32998156]
  15. Nat Commun. 2018 Mar 5;9(1):939 [PMID: 29507284]
  16. Nature. 2021 Mar;591(7848):92-98 [PMID: 33307546]
  17. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12538-43 [PMID: 22802639]
  18. Cell. 2007 Nov 30;131(5):861-72 [PMID: 18035408]
  19. Trends Pharmacol Sci. 2020 Aug;41(8):513-517 [PMID: 32553545]